Why Questcor Is Significantly Undervalued

Jun.19.12 | About: Mallinckrodt PLC (MNK)

As part of our process, we perform a rigorous discounted cash-flow methodology that dives into the true intrinsic worth of companies. In Questcor Pharma's (QCOR) case, we think the firm is undervalued. In this article, we'll explain why. But before you dig deeper into our views, please take a look at the video that explains how to read our reports.

For some background, we think a comprehensive analysis of a firm's discounted cash-flow valuation and relative valuation versus industry peers is the best way to identify the most attractive stocks at the best time to buy. This process culminates in what we call our Valuentum Buying Index (click here for more info on our methodology), which ranks stocks on a scale from 1 to 10, with 10 being the best.

If a company is undervalued both on a DCF and on a relative valuation basis, it scores high on our scale. Questcor Pharma posts a VBI score of 7 on our scale, reflecting our "undervalued" DCF assessment of the firm, its neutral relative valuation versus peers, and bullish techinicals. We use Amgen (NASDAQ:AMGN), Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Human Genome (HGSI) for our peer group analysis.

Our Report on Questcor Pharma

Click to enlarge images.

Click to enlarge

Investment Considerations

Click to enlarge

Investment Highlights

Questcor Pharma's business quality (an evaluation of our ValueCreation™ and ValueRisk™ ratings) ranks among the best of the firms in our coverage universe. The firm has been generating economic value for shareholders with relatively stable operating results for the past few years, a combination we view very positively.

Although we think the firm's DCF valuation indicates a potential attractive investment opportunity, we'd be more comfortable investing in the firm if it was more attractively priced on a relative basis vs. peers as well.

Questcor Pharma has an excellent combination of strong free cash flow generation and low financial leverage. We expect the firm's free cash flow margin to average about 37% in coming years, and the firm had no debt as of last quarter.

The company's stock price has outperformed the benchmark during the last quarter, and its valuation still looks interesting at these levels. Investors could be accumulating shares, as the stock continues to trade at bargain-basement levels.

Click to enlarge

Economic Profit Analysis

The best measure of a firm's ability to create value for shareholders is expressed by comparing its return on invested capital with its weighted average cost of capital (OTC:WACC). The gap or difference between ROIC and WACC is called the firm's economic profit spread. Questcor Pharma's three-year historical return on invested capital (without goodwill) is 856.1%, which is above the estimate of its cost of capital of 11.8%. As such, we assign the firm a ValueCreation™ rating of Excellent. In the chart below, we show the probable path of ROIC in the years ahead based on the estimated volatility of key drivers behind the measure. The solid grey line reflects the most likely outcome, in our opinion, and represents the scenario that results in our fair value estimate.

Click to enlarge

Click to enlarge

Click to enlarge

Cash Flow Analysis

Click to enlarge

Firms that generate a free cash flow margin (free cash flow divided by total revenue) above 5% are usually considered cash cows. Questcor Pharma's free cash flow margin has averaged about 38.3% during the past three years. As such, we think the firm's cash flow generation is relatively STRONG. The free cash flow measure shown above is derived by taking cash flow from operations less capital expenditures and differs from enterprise free cash flow (FCFF), which we use in deriving our fair value estimate for the company. At Questcor Pharma, cash flow from operations increased about 114% from levels registered two years ago, while capital expenditures expanded about materially over the same time period.

Valuation Analysis

Our discounted cash flow model indicates that Questcor Pharma's shares are worth between $58.00 - $88.00 each. The margin of safety around our fair value estimate is driven by the firm's Low ValueRisk™ rating, which is derived from the historical volatility of key valuation drivers. The estimated fair value of $73 per share represents a price-to-earnings (P/E) ratio of about 60.5 times last year's earnings and an implied EV/EBITDA multiple of about 39.9 times last year's EBITDA. Our model reflects a compound annual revenue growth rate of 34.6% during the next five years, a pace that is higher than the firm's three-year historical compound annual growth rate of 31.8%. Our model reflects a five-year projected average operating margin of 59.6%, which is above Questcor Pharma's trailing three-year average. Beyond year five, we assume free cash flow will grow at an annual rate of 6.9% for the next 15 years and 3% in perpetuity. For Questcor Pharma, we use a 11.8% weighted average cost of capital to discount future free cash flows.

Click to enlarge

Click to enlarge

Click to enlarge

Margin of Safety Analysis

Our discounted cash flow process values each firm on the basis of the present value of all future free cash flows. Although we estimate the firm's fair value at about $73 per share, every company has a range of probable fair values that's created by the uncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future was known with certainty, we wouldn't see much volatility in the markets as stocks would trade precisely at their known fair values. Our ValueRisk™ rating sets the margin of safety or the fair value range we assign to each stock. In the graph below, we show this probable range of fair values for Questcor Pharma. We think the firm is attractive below $58 per share (the green line), but quite expensive above $88 per share (the red line). The prices that fall along the yellow line, which includes our fair value estimate, represent a reasonable valuation for the firm, in our opinion.

Click to enlarge

Click to enlarge

Future Path of Fair Value

We estimate Questcor Pharma's fair value at this point in time to be about $73 per share. As time passes, however, companies generate cash flow and pay out cash to shareholders in the form of dividends. The chart below compares the firm's current share price with the path of Questcor Pharma's expected equity value per share over the next three years, assuming our long-term projections prove accurate. The range between the resulting downside fair value and upside fair value in Year 3 represents our best estimate of the value of the firm's shares three years hence. This range of potential outcomes is also subject to change over time, should our views on the firm's future cash flow potential change. The expected fair value of $102 per share in year three represents our existing fair value per share of $73 increased at an annual rate of the firm's cost of equity less its dividend yield. The upside and downside ranges are derived in the same way, but from the upper and lower bounds of our fair value estimate range.

Click to enlarge

Pro Forma Financial Statements

Click to enlarge

Click to enlarge

Click to enlarge

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.